Novo Nordisk: FDA may add warnings to liraglutide's label

08/19/2008 | Bloomberg · Reuters

Novo Nordisk said the FDA may call for stronger warnings on liraglutide, an experimental diabetes medicine, after two patients who took Byetta -- a similar drug from Amylin Pharmaceuticals and Eli Lilly and Co. -- died because of inflamed pancreases. The agency is working to revise the label for Byetta, which belongs to a class of drugs called incretin mimetics. Novo Nordisk said it found no proof of a "statistically significant" increase in cases of pancreatitis in clinical-trial patients treated with liraglutide.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC